Abstract
BackgroundOncolytic peptides are emerging as attractive candidates for the development of novel anticancer regimens1, reflecting broad cytolytic activities against a variety of malignant (but not normal) cells and a pronounced...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
